A novel, de novo mutation in PRKAG2 gene: infantile-onset phenotype and signaling pathway 1 involved 2 3 Abstract 20 PRKAG2 encodes the γ2-subunit isoform of the 5' AMP-activated protein kinase (AMPK), a 21 heterotrimeric enzyme with major roles in regulation of energy metabolism in response to cellular 22 3 46
stress. Mutations in PRKAG2 have been implicated in a unique hypertrophic cardiomyopathy 23 (HCM) characterized by cardiac glycogen overload, ventricular preexcitation and hypertrophy. We 24 identified a novel, de novo PRKAG2 mutation (K475E) in a neonate with prenatal onset of HCM. 25
We aimed to investigate the cellular impact, signaling pathways involved and therapeutic options 26 for K475E mutation using cells stably expressing human wild type (WT) or the K475E mutant. In 27 HEK293 cells, the K475E mutation induced a marked increase in the basal phosphorylation of T172 28 and AMPK activity, reduced sensitivity to AMP in allosteric activation and a loss of response to 29 phenformin. In H9c2 cardiomyocytes, the K475E mutation induced inhibition of AMPK and 30 reduced response to phenformin and increases in phosphorylation of P70S6K and 4E-BP1. Primary 31 fibroblasts from the patient with the K475E mutation also showed marked increases in 32 phosphorylation of P70S6K and 4E-BP1, compared to those from age-matched, non-diseased 33 controls. Moreover, overexpression of K475E induced hypertrophy in H9c2 cells which was 34 effectively reversed by treatment with rapamycin. Taken together, we have identified a novel, de 35 novo infantile-onset PRKAG2 mutation causing HCM. Our study suggests the K475E mutation 36 induces alteration in basal AMPK activity and results in a hypertrophy phenotype involving the 37 mechanistic target of rapamycin (mTOR) signaling pathway, which can be reversed with 38 rapamycin. 39 40 41 New & Noteworthy: We identified a novel, de novo PRKAG2 mutation (K475E) in the CBS3 42 repeat, a region critical for AMP binding but with no previous reported mutation. Our data suggest 43 the mutation affects AMPK activity, activates cell growth pathways and results in cardiac 44 hypertrophy which can be reversed with rapamycin. 45 rapamycin 48 49 50 52 Mutations in PRKAG2 gene, encoding the γ2 regulatory subunit isoform of AMP-activated 53 protein kinase (AMPK), cause a wide spectrum of cardiac phenotypes, including Wolff-Parkinson-54 White (WPW) syndrome (ventricular preexcitation), hypertrophic cardiomyopathy (HCM), 55 conduction system disease, significant glycogen accumulation in myocytes and sudden death 56
(2,6,10,18,21). AMPK is known as a cellular energy sensor and a major regulator of whole-body 57 energy homeostasis (15). The γ subunit of AMPK is the regulatory subunit and contains four 58 tandem repeats of a sequence called cystathionine β-synthase (CBS) motif. These motifs act in pairs 59 to form two "Bateman domains" -binding sites for AMP and ATP (4,29). During cellular energy 60 deficiency (increased ratio of AMP/ATP), binding of AMP to the Bateman domains activates 61 AMPK by inducing phosphorylation of T172 in the α subunit (kinase domain) (12,13). Activation 62 of AMPK in many tissues, including the heart, results in inhibition of ATP-consuming processes 63 and activation of catabolic processes that favor ATP generation. 64
To date, many PRKAG2 mutations have been reported. The majority of these mutations are 65 heterozygous missense mutations within one of the four CBS domains but mutations can happen 66 near the N-terminal, C-terminal or in a linker region between two CBS domains (Table 1) . 67
Case presentation: We encountered a child who presented with an abnormal 27-week prenatal 68 ultrasound, consistent with HCM. At birth, the child was noted to have significant murmur. 69
Echocardiograms confirmed the diagnosis. Electrocardiograms revealed extremely short PR interval 70 and combined ventricular hypertrophy ( Figure 1C ). Molecular testing for a hypertrophic 71 cardiomyopathy panel revealed a novel, de novo likely pathogenic variant in the PRKAG2 gene 72
[AAA (lysine 475) to GAA (glutamic acid) or K475E]. This variant is located in the CBS3 repeat, 73
an area that has no previous report of mutation and is conserved in all species (Table 1, Figure 1B) . 74
At three years of age, the child has modest HCM and is on supportive medication. She is otherwise 75 developing normally. Family investigation: No family history of sudden cardiac death. Neither 76 parent had abnormal cardiac echocardiograms or electrocardiograms. Molecular testing for 77 PRKAG2 in both parents was normal ( Figure 1A) . 78
To investigate the significance of the de novo K475E mutation on the AMPK complex, we 79 stably expressed human PRKAG2 wild type (WT) and K475E in HEK293 cells and H9c2 80 5 cardiomyocytes to examine AMPK activity, biochemical function and signaling pathways involved 81 resulted from the K475E mutation. Primary fibroblasts from the patient with the K475E mutation 82 were obtained for clinical purposes and institutional review board approval was obtained for further 83 research study. Primary fibroblasts obtained from commercial sources and age-and sex-matched 84 individuals were obtained and used as controls. The potential of mechanistic target of rapamycin 85 (mTOR) inhibition as a targeted therapeutic approach for mutation-induced HCM was also 86 investigated using the rat H9c2 embryonic cardiomyocytes. We demonstrated that the K475E 87 mutation induced changes in the AMPK complex in a way very different from other PRKAG2 88 mutations. The K475E mutation in H9c2 cells results in activation of cell growth pathways and 89 hypertrophy, which can be attenuated by inhibition of mTOR. 90 91
Genetic testing 93
Hypertrophic cardiomyopathy next generation sequencing panel testing was sent to a CLIA 94 (Clinical Laboratory Improvement Amendments) certified laboratory (GeneDx, Gaithersburg, MD) 95
December 2010. Genomic DNA was extracted, amplified and sequenced by solid-state sequencing -96 by-synthesis process. The DNA sequence was assembled and analyzed in comparison with the 97 published genomic reference sequences. This panel included the complete coding and splice region 98 of the following eighteen genes known to be associated with HCM: MYH7, MYBPC3, TNNT2, 99 hydrocortisone (1 µg/ml), human epidermal growth factor (10 ng/ml), basic fibroblast growth factor 116 (3 ng/ml), and heparin (10 µg/ml). The cells were used between passages 2 and 6. 80-100% 117 confluent cells were used for western blot experiment. Media was changed once daily starting at 118 day 2 and until the termination of the experiment. Life Technologies) for 20 minutes at 37 °C. Cells were washed 5 times with DPBS. Cell size was 146 assessed by fluorescence microscopy using an inverted microscope at 20x objective (Nikon Eclipse 147 TE2000-E, CCD camera). Sixty to eighty random cell images were taken per plate and the cell 148 areas were determined by Image J software. In another series of related experiments, H9c2 cells 149 were treated with or without rapamycin for 3.5, 4, or 5 days. At each time point cells were stripped 150 and re-plated exactly 24 hours before being harvested and stained for fluorescence microscopy. Cell 8 hypertrophy was also confirmed using flow cytometry. Cells were trypsinized and analyzed by flow 152 cytometry using a FACSCanto™ system (BD Biosciences, Franklin Lakes, NJ). Forward scatter 153 (FSC) was used to measure cell volume. For each condition 10,000 cells were counted. FSC 154 detector gain was kept constant between samples to allow direct comparison of samples. 155
156
Statistics 157
Statistical significance of the differences between groups was analyzed using paired Student's t 158 test or ANOVA followed by Newman-Keuls test. All data were expressed as mean ± S.E. based on 159 results derived from three to four independent experiments. A probability of P < 0.05 was 160 considered to represent a significant difference. 161 162
Genetic testing result 164
The proband was found to carry a heterozygous novel missense likely pathogenic variant in 165 PRKAG2 gene. The nucleic acid substitution at cDNA level was c.1423 A>G resulting in amino 166 acids alteration from lysine to glutamic acid (K475E). This change in PRKAG2 has not been 167 published and is not a known benign polymorphism. K475E represents a nonsynonymous 168 substitution of negatively charged glutamic acid for positively charged lysine residue in a highly 169 conserved across species throughout evolution and gene isoforms. In addition, in silico analysis 170 tested at the laboratory, indicating it is not a common benign variant. In addition, the parents who 175 are both clinically asymptomatic, had normal ECG and cardiac echo were not found to carry this 176 variant. Base on this information, we concluded that the K475E in PRKAG2 is most consistent with 177 a de novo pathogenic variant. 178
179
The K475E mutation markedly increases basal AMPK activity and reduces response to phenformin 180 in HEK293 cells 181
To investigate the molecular effects of the K475E mutation on the function of the AMPK 182 complex, we generated HEK-293 cells stably expressing either the human WT or K475E mutant 183 FLAG-tagged γ2 from a tetracycline-inducible promoter. We have shown previously using this 184 system that the expressed γ2 subunit binds to the endogenous α and β subunits (primarily α1 and β1 185 in HEK-293 cells), partially replacing the endogenous γ1 subunit (14). Following induction with 186 tetracycline, AMPK complexes containing the WT or K475E γ2 subunits were immunoprecipitated 187 from unstressed cells using anti-FLAG antibodies and their activities determined at varying AMP 188 concentrations. When assayed in the absence of AMP, the activity of the K475E complex was 8-189
fold higher than that of the WT complex ( Figure 2A ). However, while the WT complex was 190 allosterically activated almost 4-fold by low concentrations of AMP (half-maximal effect, 6 µM), 191 the K475E mutant was only modestly activated (about 50%) and then only at much higher 192 concentrations (EC 50 ≈ 90 µM). The different degrees of allosteric activation of the WT and K475E 193 mutant by AMP were particularly evident when the activities were expressed relative to the 194 activities measured in the absence of AMP ( Figure 2B ). 195
We next compared the effects of metabolic stress induced by the drug phenformin on AMPK in 196 HEK-293 cells stably expressing WT γ2, the K475E mutation, or another γ2 mutation (R531G), 197 which is associated with an inherited form of hypertrophic cardiomyopathy with childhood onset 198 (11). The WT, K475E or R531G complexes were immunoprecipitated using anti-FLAG antibodies 199
and their activities measured at optimal AMP concentration (200 µM). As expected, phenformin 200 caused a 4-fold increase in WT AMPK activity that was associated with a similar increase in T172 201 phosphorylation ( Figure 3 ). As reported previously (14), complexes containing the R531G mutation 202 exhibited modest (1.5-2-fold) increases in basal activity and T172 phosphorylation compared with 203 the WT (although these differences were not statistically significant in this dataset), but there were 204 no further increases in these parameters in response to phenformin. By contrast, complexes 205 containing the K475E mutation exhibited large increases in basal activity and T172 phosphorylation 206
(5-and 7-fold, respectively) compared to the WT, although once again there were no further 207 increases in these parameters in response to phenformin ( Figure 3) . Thus, the K475E mutation 208 yields a much larger increase in basal and kinase activity and T172 phosphorylation than the R531G 209 mutation, but like the latter has a greatly reduced sensitivity to AMP and/or ADP, both for allosteric 210 activation and for enhanced T172 phosphorylation. 211
We also used atomic co-ordinates from crystal structures of partial AMPK complexes with 212 bound AMP, ADP or ATP (9,31), to examine the location of K475 with respect to these regulatory 213 nucleotides. The available structures are of complexes containing γ1 rather than γ2, but K475 is 214 conserved in rat γ1 as K242. Interestingly, the nitrogen atom on the K242 side chain is within 4-5 Å 215 of free oxygen atoms of the α-, β-or γ-phosphate groups of AMP, ADP or ATP bound in site 1 216 (Figures 4A-C), suggesting that K242 forms electrostatic interaction with phosphate groups of all 217 three nucleotides. We also noted that K242 was located close to R223, a residue within the CBS3 218 repeat that is conserved in all vertebrate γ subunit sequences. Although the side chain of R223 219 points away from K242 (and the nucleotide phosphate groups) in the structures determined, if K475 220 was replaced with glutamate it seems feasible that the side chain of R223 could rotate to form a salt 221 bridge with it. 222 γ1 and γ2 isoforms (illustrated by the human and chicken sequences), and in Drosophila 224 melanogaster, Caenorhabditis elegans (γ1 isoform) and Giardia lamblia ( Figures 4D, Figure 1B) . 225
In vertebrate γ3 isoforms and in some other invertebrate orthologues there is another basic residue 226 (arginine) at this position. Figure 4D also shows that a basic residue is not conserved at this position 227 in fungi (Schizosaccharomyces pombe and Saccharomyces cerevisiae) or higher plants (Arabidopsis 228 thaliana); interestingly, the orthologues in these species are not allosterically activated by AMP. The effect of phenformin, however, was significantly reduced in the K475E-expressing cells, 241 compared to the WT-expressing cells ( Figure 5A & B) . The cell size difference between the WT-242 and K475E-expressing H9c2 cells was analyzed using flow cytometry. We found a small but 243 noticeable increase in cell size of the K475E mutant-expressing cells as compared to WT-244 expressing cells ( Figure 5C ). Western blots were performed on cell lysates from H9c2 cell expressing the WT or K475E. As 249 shown in Figure 6 , K475E-expressing cells had significantly increased phosphorylation of p70S6K 250 and 4EBP1, compared to the WT-expressing cells. Phosphorylation at T-389 is critical for p70S6K 251 activation and is considered rapamycin-sensitive (7). 4E-BP1, a translation repressor protein, 252 residues leads to its dissociation from eIF4E thus results in activation of cap-dependent mRNA 254 translation (25). Therefore, phosphorylation of p70S6K and 4E-BP1 was used as readout for 255 cellular growth. Phosphorylation of 4E-BP1 at T37/T46, S65 and T70 were all significantly 256 increased in K475E-expressing cells, compared to WT-expressing cells ( Figure 6 ). In contrast, Akt 257 phosphorylation (S473, T308) was not changed. 258
Western blot experiments described above were repeated using primary fibroblast from the 259 patient with the K475E mutation and multiple age-and sex-matched controls. Similarly, fibroblasts 260 carrying the K475E mutation had significant increases in phosphorylation of p70S6K and 4E-BP1, 261 compared to the controls (Figure 7) . Again, phosphorylation of Akt was not changed. 262
Taken together, these results suggest the K475E mutation results in an Akt-independent 263 activation of cell growth pathway. One possibility for the lack of phenotype 'rescue' following rapamycin treatment is that a 24-280 hour treatment regimen may not be sufficient. We therefore examined the time-course effect of 281 rapamycin on H9c2 cell hypertrophy. The WT-and K475E-expressing cells were treated with or 282 13 without rapamycin for 1, 3.5, 4, or 5 days. In both cell groups, cell size increased significantly after 283 longer incubation time (over 3.5 Days, Figure 9A ). While the cell size of WT-expressing cells 284 reached a plateau at day 3.5, those of K475E-expressing continued to increase. In WT-expressing 285 cells, treatment of rapamycin effectively reduced the increases in cell size on days 3.5 and 4 but the 286 effect seemed to taper off on day 5. In contrast, the effect of rapamycin remained effective in 287 reducing the size of K475E-expressing cells with the effect becoming even more obvious at day 5 288 when the cell sizes of rapamycin-treated K475E-expressing cell were comparable to that of WT-289 expressing cells at day 5 ( Figure 9B ). Taken together, these data demonstrated mTOR inhibition by 290 rapamycin can be an effective therapeutic approach for K475E mutation induced hypertrophy. 291
293
Mutations in PRKAG2 induce a wide range of cardiac phenotypes, including glycogen overload, 295 ventricular preexcitation, conduction diseases and hypertrophy. Many mutations have an early-296 onset cardiac phenotype, as the case for K475E. Given that identification of this disease can be 297 challenging (patient with an infantile-onset mutations may die in utero or during early postnatal 298 life) and misdiagnosis frequently happens (for example confusion with Pompe disease, a glycogen 299 storage disease), it is likely the incidence of PRKAG2-induced HCM is underreported. Our study 300 revealed a mutation located in the CBS3 repeat, which has no previous reported mutation, and 301 behaved quite differently in terms of changes in AMPK activity and allosteric activation from other 302 PRKAG2 mutations. Moreover, our data suggest that targeted therapy of PRKAG2-induced HCM 303 using mTOR inhibition should be considered. 304
Our molecular studies in HEK293 cells show that the K475E mutation has three effects on the 305 regulation of the AMPK complex: (i) markedly increasing the basal phosphorylation of T172 and 306 hence basal kinase activity; (ii) reducing the sensitivity to AMP in allosteric activation; (iii) 307 preventing the increase in T172 phosphorylation observed in response to phenformin, which 308 increases cellular ADP:ATP and AMP:ATP ratios. The three nucleotide-binding sites (1, 3 and 4) in 309 the AMPK-γ subunit are numbered by convention according to the number of the CBS repeat that 310 carries an aspartate side chain interacting with the 2'-and 3'-hydroxyls of the nucleotide ribose ring 311 (17). The structural analysis illustrated in Figure 4 suggests that K242 in γ1 (equivalent to K475 in 312 γ2) is involved in forming electrostatic interactions with phosphate groups of all three adenine 313 nucleotides, AMP, ADP and ATP, in site 1. Interestingly, a lysine at this position is conserved in all 314 vertebrate γ1 and γ2 isoforms, and also in some invertebrate orthologues such as that from 315 Drosophila melanogaster; in vertebrate γ3 isoforms and many other invertebrate orthologues it is 316 replaced by another basic residue, arginine. A basic residue at this position is not, however, 317 conserved in the fungal and plant Arabidopsis thaliana, where allosteric activation by AMP is not 318 observed ( Figure 4D ). The K475E mutation replaces the positively charged amine of lysine with the 319 negatively charged carboxyl group of glutamate, potentially disrupting electrostatic interactions 320 with all three nucleotides. Although it is difficult to predict the relative effects this might have on 321 binding of the three nucleotides, if it had a larger effect on the binding of AMP than ATP it would 322 be expected that higher concentrations of AMP would be required to displace ATP from site 1. 323 fold higher than that of the wild type ( Figure 2) . The maximal degree of activation by AMP also 325 appeared to be reduced, although analysis of this was hindered by the fact AMP starts to inhibit 326 AMPK at concentrations above 200 µM, due to competition with ATP at the catalytic site. 327
Xiao et al (32) originally proposed that the effects of AMP on allosteric activation were entirely 328 due to binding at site 1, whereas the effects of AMP and/or ADP on T172 dephosphorylation were 329 due to binding at site 3. Since K242 in γ1 only seems to interact with nucleotides in site 1, the 330 model of Xiao et al (32) is consistent with our data showing that the K475E mutation markedly 331 affects allosteric activation by AMP ( Figure 2B ). However, there were also major effects of the 332 K475E mutation to increase the basal T172 phosphorylation and hence basal activity, while 333 preventing further phosphorylation induced by phenformin-triggered metabolic stress in intact cells. 334
These effects observed in HEK293 cells are less easy to explain using the simple model of Xiao et 335 al (32). The three nucleotide-binding sites in the γ subunit lie very close together, and the side 336 chains of some conserved basic residues (e.g. H150 and H297 in rat γ1) make interactions with the 337 phosphate groups of more than one nucleotide (31). It is therefore not surprising that mutations 338 affecting binding of a nucleotide at one site can also affect binding and function at other sites. For 339 example, mutation to alanine of any one of the three aspartate residues that define sites 1, 3 and 4 340 (D89 in CBS1, D244 in CBS3 and D316 in CBS4, rat γ1) affects not only allosteric activation but 341 also T172 phosphorylation (24). That the model of Xiao et al (32) is an oversimplification is also 342 suggested by a recent study in which a core AMPK complex was crystallized in the presence of 343 ATP rather than AMP. In this structure, ATP was found in sites 1 and 4, with site 3 being empty; it 344 was also suggested that the mode of ATP binding in site 4 would preclude binding of any 345 nucleotide at site 3 (9). Xiao et al had previously proposed that site 4 was a "non-exchangeable" site 346 at which AMP bound tightly and irreversibly (31). It is clear that the roles of the three γ subunit 347 nucleotide-binding sites on AMPK function are complex, and remain incompletely understood. 348
Of the three effects of the K475E mutation on AMPK function, which is the most likely to and the reduced ability of cellular stresses such as phenformin to increase T172 phosphorylation as 352 seen in both HEK293 and H9c2 cells. We suspect that these effects could be compensated for by 353 human heart (19,26), and appears to account for about 80% of total AMPK activity in adult rat heart 355 (13). Both the de novo and inherited mutations in the PRKAG2 gene are dominant in effect, and 356 increased basal activity and T172 phosphorylation have been previously reported for the R531G, 357 R531Q and R384T mutations, with both of the latter being de novo mutations that caused severe 358 disease leading to death in early life (1,8). Our study in H9c2 cells showed a significant reduction in 359 T172 phosphorylation and reduced response to phenformin. Thus, cell environment appears to be 360 important in studying this gene mutation. The K475E mutation induced inhibition of AMPK 361 observed in H9c2 cells is in agreement with the structural modeling results where the mutation 362 causes disruption of electrostatic interactions with adenine nucleotides. Activation of AMPK is well 363 known to inhibit downstream signaling pathway, including the mTOR which plays a critical roles in 364 regulation of cell growth. Since we observed a markedly increases in phosphorylation of p70S6K, 365 S6 and 4E-BP1 in K475E expressing H9c2 cells and the patient with the mutation, a loss-of-366 function K475E phenotype seems logical. 367 mTOR functions by interacting with several adaptor proteins to form two distinct multiprotein 368 complexes: mTOR complex 1 (mTORC1) and mTORC2. mTORC1 is a critical regulator of protein 369 synthesis, cell growth and proliferation and many other metabolic processes (28). p70S6K is 370 required for G1 cell cycle progression and cell growth. Phosphorylation of p70S6K is required for 371 its activation and T389 is the principal regulatory phosphorylation site. 4E-BP1 is a translation 372 repressor protein. It functions by binding to the eukaryotic translation initiation factor 4E (eIF4E). 373
Only when being hyperphosphorylated would 4E-BP1 stop interaction with eIF4E which results in 374 activation of cap-dependent translation (25). Since both p70S6K and 4E-BP1 are considered 375 downstream of mTORC1 and can be phosphorylated by mTOR, we examined phosphorylation of 376 these two critical signaling factors to determine changes in cell growth response by the K475E 377 mutation. We observed significant increases in p70S6K phosphorylation at T389 as well as Ser-378 421/T424 sites with the K475E mutation. Not surprisingly ribosomal protein S6 phosphorylation 379 (S235/S236 and S240/S244) was also significantly increased. A noted hyper-phosphorylation was 380 also found with the K475E mutation. These changes were consistent in H9c2 cells as well as in the 381 patient fibroblasts. These observations suggest that the K475E mutation induces activation of cell 382 growth pathway downstream of mTOR. Our next step, logically, is to test the therapeutic potential 383 we demonstrated that cell hypertrophy induced by the K475E mutation can be reversed by 385 rapamycin. This is encouraging as to date there is no targeted therapy for PRKAG2 HCM. Hence, 386 the next step would be to develop transgenic mouse models to demonstrate the effectiveness of the 387 mTOR inhibition strategy in treating PRKAG2 mutation-induced HCM. 388
Overall, our data show that a novel, de novo K475E PRKAG2 mutation causing hypertrophic 389 cardiomyopathy. The K475E mutation induces changes in the AMPK complex that are not shared 390 by the other PRKAG2 mutations. The K475E mutation also induces activation of cell growth 391 pathways and hypertrophy which can be effectively reversed by rapamycin treatment. 392 393
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